GenAssist Therapeutics

company

About

GenAssist Therapeutics develops gene therapy drugs using base editing technology, which is advantageous in the field of DMD treatment.

  • 1 - 10

Details

Last Funding Type
Series A
Industries
Biotechnology,Health Care,Medical,Therapeutics
Founded date
Jan 1, 2020
Number Of Employee
1 - 10
Operating Status
Active

GenAssist Therapeutics develops gene therapy drugs using base editing technology, which is advantageous in the field of DMD treatment. Founded in 2020, GenAssist was founded by outstanding scientists and industry experts in July 2020. They are committed to the development of gene editing drugs for a variety of genetic diseases.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
GenAssist Therapeutics has raised a total of — in funding over 2 rounds. Their latest funding was raised on Dec 8, 2022 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 8, 2022 Series A 1 AstraZeneca Detail

Investors

Number of Lead Investors
Number of Investors
1
1
GenAssist Therapeutics is funded by 1 investors. AstraZeneca are the most recent investors.
Investor Name Lead Investor Funding Round
AstraZeneca Yes Series A